Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Palfinger, Sanochemia (18/02/2019)

24.02.2019

Palfinger: Palfinger, manufacturer of innovative lifting solutions, iincreased revenues in 2018 by 9.8 per cent to Euro 1.6 bn, a new record level in the Company’s history. In 2018, EBIT increased to Euro 127.0 mn (2017: 27.8 mn), which means that despite comprehensive restructuring measures, Palfinger achieved a new peak in its corporate history. In the 2018 financial year, the EBIT margin amounted to 7.9 per cent, return on capital employed came to 8.5 per cent, which is significantly higher than the previous year’s figure of 1.7 per cent. The consolidated net result came to Euro 58.0 mn. A dividend of Euro 0.51 per share (previous year: 0,47 Euro) will be proposed for distribution. “We are utilizing the market position and sound economic performance of our Company to prepare for greater volatility in the markets and a difficult economic environment,” commented Andreas Klauser, CEO of Palfinger AG, explaining the rationale behind the re-orientation. “As an integrated group, Palfinger will be able to be more flexible and profitable in its operations. Internally, we have identified a great deal of potential we will utilize to grow further. The greatest support in this regard is our GPO, a valuable tool in ensuring global and efficient management.”
Palfinger: weekly performance: 0.00%

Sanochemia: Listed Sanochemia Pharmazeutika AG announced the inception of its Phase 2 clinical trial (USA) sponsored by partner Neurana Pharmaceuticals Inc. The STAR study is a double-blind, randomized placebo-controlled Phase 2 dose-finding study to investigate the efficacy and safety of tolperisone. The study includes approximately 400 patients with back pain caused by or associated with muscle cramps. The study will be conducted at approximately 45 US study centers. Tolperisone is a muscle relaxant used for the symptomatic treatment of spasticity.
Sanochemia: weekly performance: 12.59%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (18/02/2019)


Partners









latest 21st Austria

21st Austria weekly - Palfinger, Sanochemia (18/02/2019)


24.02.2019, 1981 Zeichen



Palfinger: Palfinger, manufacturer of innovative lifting solutions, iincreased revenues in 2018 by 9.8 per cent to Euro 1.6 bn, a new record level in the Company’s history. In 2018, EBIT increased to Euro 127.0 mn (2017: 27.8 mn), which means that despite comprehensive restructuring measures, Palfinger achieved a new peak in its corporate history. In the 2018 financial year, the EBIT margin amounted to 7.9 per cent, return on capital employed came to 8.5 per cent, which is significantly higher than the previous year’s figure of 1.7 per cent. The consolidated net result came to Euro 58.0 mn. A dividend of Euro 0.51 per share (previous year: 0,47 Euro) will be proposed for distribution. “We are utilizing the market position and sound economic performance of our Company to prepare for greater volatility in the markets and a difficult economic environment,” commented Andreas Klauser, CEO of Palfinger AG, explaining the rationale behind the re-orientation. “As an integrated group, Palfinger will be able to be more flexible and profitable in its operations. Internally, we have identified a great deal of potential we will utilize to grow further. The greatest support in this regard is our GPO, a valuable tool in ensuring global and efficient management.”
Palfinger: weekly performance: 0.00%

Sanochemia: Listed Sanochemia Pharmazeutika AG announced the inception of its Phase 2 clinical trial (USA) sponsored by partner Neurana Pharmaceuticals Inc. The STAR study is a double-blind, randomized placebo-controlled Phase 2 dose-finding study to investigate the efficacy and safety of tolperisone. The study includes approximately 400 patients with back pain caused by or associated with muscle cramps. The study will be conducted at approximately 45 US study centers. Tolperisone is a muscle relaxant used for the symptomatic treatment of spasticity.
Sanochemia: weekly performance: 12.59%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (18/02/2019)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #751: ATX fällt, alle Titel heute im Minus, neuer starker Partner für kapitalmarkt-stimme.at




 

Bildnachweis

Aktien auf dem Radar:Polytec Group, voestalpine, Agrana, Austriacard Holdings AG, Addiko Bank, Warimpex, OMV, VIG, Semperit, RBI, Wienerberger, Cleen Energy, DO&CO, EVN, EuroTeleSites AG, Oberbank AG Stamm, Immofinanz, Mayr-Melnhof, Amag, CA Immo, Erste Group, Flughafen Wien, Österreichische Post, S Immo, Telekom Austria, Uniqa, Nike, Covestro, Siemens Energy, Rheinmetall, Airbus Group.


Random Partner

VAS AG
Die VAS AG ist ein Komplettanbieter für feststoffbefeuerte Anlagen zur Erzeugung von Wärme und Strom mit über 30-jähriger Erfahrung. Wir planen, bauen und warten Anlagen im Bereich von 2 bis 30 MW für private, industrielle und öffentliche Kunden in ganz Europa. Wir entwickeln maßgefertigte Projekte ganz nach den Bedürfnissen unserer Kunden durch innovative Lösungen.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten